How Overseas Innovative Drugs Accelerate Approval and Manufacturing in China through Hainan’s "Lecheng R&D + Haikou Production" Model

How long does it take for an overseas innovative drug to go from birth to market entry in China, and to transition from a U.S. manufacturer to a Hainan-based production company? Less than 3 years — this is the answer given by Hainan.

Traditionally, bringing an imported innovative drug to the Chinese market required three phases of clinical trials, prolonged approvals, and local production preparations, taking anywhere from 5 to 9 years. However, the problem for international Pharma has always been: how can we reach Chinese patients faster, build brand recognition sooner, and localize at lower costs? Today, Hainan’s "Lecheng R&D + Haikou Production" model is completely rewriting the situation, enabling enterprises to enter the Chinese market more quickly.

"Lecheng R&D + Haikou Production": Complementary Roles

Hainan's "Lecheng R&D + Haikou Production" model offers a systematic solution. The core of this model lies in the integration of upstream R&A with downstream manufacturing: quick approval and Real World Research policies in the Lecheng Pilot Zone allow drugs to rapidly enter the market, while Haikou High-Tech Zone provides a comprehensive production facility, ensuring that drugs and devices are quickly manufactured and launched locally.

For instance, American company G1 successfully applied the "Lecheng R&D + Haikou Production" model for Trilaciclib (Cosela), its innovative cancer drug. Backed by Real World Data from the Lecheng, the drug received approval in just 14 months, and production was swiftly moved to Haikou. This model significantly lowered production costs and accelerated the time to market. Hainan offers not just preferential policies, but a streamlined pathway for international pharma to validate the Chinese market with reduced risk and accelerated timelines.

Upstream R&D: Boao Lecheng International Medical Tourism Pilot Zone

Located in Boao, Hainan, the Lecheng "medical special zone," enjoys national-level preferential policies, including licensed medical treatments, research, operations, and international medical exchanges. The core advantage it offers is market access: allowing overseas-approved innovative drugs and devices, but unregistered in China, to be applied to specific patients in China in a very short time frame (with approval timelines as fast as 1.6 days). The data collected from the use of these licensed products can be analyzed and used as evidence to support their formal registration with China’s National Medical Products Administration (NMPA).

For international companies, this means innovative drugs and devices can conduct clinical studies in sync with registration in China. The Real World Data can serve as supporting evidence for the drug's formal application with NMPA, significantly reducing time and lowering the cost of traditional clinical trials.

Production Base: Haikou National High-Tech Industrial Development Zone

After completing application and data collection in the Boao Lecheng, products will be transitioned into localized production. The Haikou High-Tech Zone is a core industrial cluster designed for manufacturing. Hainan is not starting from scratch; the Haikou High-Tech Zone has already gathered over 100 pharmaceutical companies, covering the entire industry chain from R&D, production to outsourced services (CRO/CDMO). Enterprises can quickly find upstream and downstream partners, greatly facilitating subsequent operations and development.

Hainan offers not only a mature industrial support system but also excellent market access conditions for overseas businesses, thanks to the FTP policies and "zero tariff" policies. The core policy benefits include tariff exemptions on processing value-added goods, a reduced corporate income tax rate of 15%, and zero tariffs on imported production equipment. If the processing value-added exceeds 30%, pharmaceutical products and medical devices manufactured in Hainan can enter the mainland Chinese market tariff-free, which reduces production costs and enhances price competitiveness in the end market.

Hainan's Advantages: Beyond Policies, Driven by Ecosystem

"Lecheng R&D + Haikou Production" model represents an innovative breakthrough in China's pharmaceutical industry, offering overseas companies a fast track to enter the Chinese market. The model has become a "strategic first choice" due to its four irreplaceable advantages:

National-Level Policy Support: From the "Overall Plan for the Construction of Hainan Free Trade Port" to the Real World Data pilot, the institutional innovation driven by government far exceeds that of ordinary zones.

Full Industry Chain Integration: Lecheng and Haikou have formed a "front store, back factory" structure, providing full process support from R&D and clinical trials to manufacturing. This integration reduces supply chain costs and streamlines customs processes, enhancing competitiveness in China.

Savings in Cost and Time: Real World Research evidence can be used for the market approval of licensed drugs and devices in China. Policies such as tariff exemptions on value-added processing, rewards for international certifications, and production incentives significantly reduce overall business costs.

Mature Industrial Clusters: The Haikou High-Tech Zone has gathered over 100 pharmaceutical companies, covering the entire industry chain, including R&D, clinical trials, production, and CRO/CDMO services. Companies can quickly tap into this ecosystem.

Hainan is positioning itself as the strategic first choice for international innovative drugs entering China. For overseas pharma, this is not only a low-risk platform for testing the Chinese market but also an effective opportunity to capture a share of China, the world's second-largest healthcare market.

Related Articles